The english version of the website of the School of Medicine is under development


Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.

TitleUse of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.
Publication TypeJournal Article
Year of Publication2017
AuthorsIosifidis, E., Violaki A., Michalopoulou E., Volakli E., Diamanti E., Koliouskas D., Antachopoulos C., Drossou-Agakidou V., Sdougka M., & Roilides E.
JournalJ Pediatric Infect Dis Soc
Date Published2017 Jun 01
KeywordsAdolescent, Anti-Bacterial Agents, Bacteremia, Child, Child, Preschool, Cross Infection, Drug Resistance, Multiple, Bacterial, Female, Gram-Negative Bacteria, Gram-Negative Bacterial Infections, Humans, Infant, Male, Minocycline, Respiratory Tract Infections, Retrospective Studies, Treatment Outcome

Background.: Emergence of extensively drug-resistant (XDR) bacteria has forced clinicians to use off-label antimicrobial agents such as tigecycline. We present our experience on salvage use of tigecycline for the treatment of infections caused by XDR Gram-negative bacteria in critically ill children and review published cases.Methods.: We conducted a retrospective chart review in pediatric departments of a tertiary level hospital from January 2009 to May 2014. Patients were identified using pharmacy database. For the literature review, relevant articles were identified from PubMed.Results.: In our case series, 13 children (7 males) with a median age of 8 years (range, 2.5 months-14 years) received tigecycline for ≥2 days as treatment for healthcare-associated infections including 5 bacteremias, 6 lower respiratory tract infections, and 3 other infections. Isolated pathogens were XDR Gram-negative bacteria except 1. A loading dose (range, 1.8-6.5 mg/kg) was given in all except 2 cases. Maintenance dose was given at 1-3.2 mg/kg q12 h. Other antimicrobials including colistin and aminoglycosides (85% and 62%, respectively) were coadministered to all patients. No serious adverse events were detected in these very ill children. Twenty cases of children treated with tigecycline were previously published, mostly for multidrug-resistant/XDR bacteria. An episode of acute pancreatitis and neutrophil engraftment delay in 2 cases were reported during tigecycline treatment. Analyzing reported and all our cases together, mortality in bloodstream infections was 86%, whereas in nonbacteremic cases it was 24% (P = .009).Conclusions.: Tigecycline, given at the range of administered doses as salvage therapy and in combination with other antimicrobial agents, seemed to be well tolerated in a series of mainly critically ill pediatric patients and demonstrated relatively good clinical response in nonbacteremic patients.

Alternate JournalJ Pediatric Infect Dis Soc
PubMed ID27000866


Secretariat of the School of Medicine


Schoole of Medicince presence in social networks
Follow Us or Connect with us.